Upload
rofi-irman
View
214
Download
0
Embed Size (px)
Citation preview
7/31/2019 Von willbread.pdf
1/126
von Willebrand Disease
F U L L R E P O R T
The Diagnosis, Evaluation, and Management of
7/31/2019 Von willbread.pdf
2/126
7/31/2019 Von willbread.pdf
3/126
von Willebrand Disease
The Diagnosis, Evaluation, and Management of
NIH Publication No. 08-5832
December 2007
7/31/2019 Von willbread.pdf
4/126
7/31/2019 Von willbread.pdf
5/126
NHLBI von Willebrand DiseaseExpert Panel
Chair
William L. Nichols, Jr., M.D. (Mayo Clinic,Rochester, MN)
Members
Mae B. Hultin, M.D. (Stony Brook University, StonyBrook, NY); Andra H. James, M.D. (Duke UniversityMedical Center, Durham, NC); Marilyn J. Manco-Johnson, M.D. (The University of Colorado at Denverand Health Sciences Center, Aurora, CO, and The
Childrens Hospital of Denver, CO); Robert R.Montgomery, M.D. (BloodCenter of Wisconsin andMedical College of Wisconsin, Milwaukee, WI);Thomas L. Ortel, M.D., Ph.D. (Duke UniversityMedical Center, Durham, NC); Margaret E. Rick,M.D. (National Institutes of Health, Bethesda, MD);J. Evan Sadler, M.D., Ph.D. (Washington University,St. Louis, MO); Mark Weinstein, Ph.D. (U.S. Foodand Drug Administration, Rockville, MD); BarbaraP. Yawn, M.D., M.Sc. (Olmsted Medical Center andUniversity of Minnesota, Rochester, MN)
National Institutes of Health StaffRebecca Link,Ph.D. (National Heart, Lung, and Blood Institute;
Bethesda, MD); Sue Rogus, R.N., M.S. (NationalHeart, Lung, and Blood Institute, Bethesda, MD)
Staff
Ann Horton, M.S.; Margot Raphael; Carol Creech,M.I.L.S.; Elizabeth Scalia, M.I.L.S.; Heather Banks,M.A., M.A.T.; Patti Louthian (American Institutesfor Research, Silver Spring, MD)
Financial and Other Disclosures
The participants who disclosed potential conflicts
were Dr. Andra H. James (medical advisory panel forZLB Behring and Bayer; NHF, MASAC), Dr. MarilynManco-Johnson (ZLB Behring Humate-P StudySteering Committee and Grant Recipient, WyethSpeaker, Bayer Advisor and Research Grant Recipient,Baxter Advisory Committee and Protein C StudyGroup, Novo Nordisk Advisory Committee), Dr.Robert Montgomery (Aventis Foundation Grant;GTI, Inc., VWFpp Assay; ZLB Behring and BayerAdvisory Group; NHF, MASAC), and Dr. WilliamNichols (Mayo Special Coagulation Laboratoryserves as central lab for Humate-P study by ZLB
Behring). All members submitted financialdisclosure forms.
ivon Willebrand Disease
7/31/2019 Von willbread.pdf
6/126
ii von Willebrand Disease
7/31/2019 Von willbread.pdf
7/126
7/31/2019 Von willbread.pdf
8/126
Contents (continued)
Opportunities and Needs in VWD Research,Training, and Practice 57Pathophysiology and Classification of VWD 57Diagnosis and Evaluation 58Management of VWD 58Gene Therapy of VWD 59Issues Specific to Women 59Training of Specialists in Hemostasis 59
References 60
Evidence Tables 83Evidence Table 1. Recommendation I.B. 84Evidence Table 2. Recommendation II.B 85Evidence Table 3. Recommendation II.C.1.a 87Evidence Table 4. Recommendation II.C.1.d 90Evidence Table 5. Recommendation II.C.2 91Evidence Table 6. Recommendation IV.C 92Evidence Table 7. Recommendation VI.A 94Evidence Table 8. Recommendation VI.C 96Evidence Table 9. Recommendation VI.D 98Evidence Table 10. Recommendation VI.F 100Evidence Table 11. Recommendation VII.A 103Evidence Table 12. Recommendation VII.C 107Evidence Table 13. Recommendation X.B 111
List of Tables
Table 1. Level of Evidence 3Table 2. Synopsis of VWF Designations Properties,
and Assays 6Table 3. Nomenclature and Abbreviations 7Table 4. Classification of VWD 12Table 5. Inheritance, Prevalence, and Bleeding
Propensity in Patients Who Have VWD 12Table 6. Bleeding and VWF Level in Type 3 VWD
Heterozygotes 16Table 7. Common Bleeding Symptoms of Healthy
Individuals and Patients Who HaveVWD 21
Table 8. Prevalences of Characteristics in PatientsWho Have Diagnosed Bleeding DisordersVersus Healthy Controls 23
Table 9. Influence of ABO Blood Groups onVWF:Ag 31
Table 10. Collection and Handling of PlasmaSamples for Laboratory Testing 33
Table 11. Intravenous DDAVP Effect on PlasmaConcentrations of FVIII and VWF inNormal Persons and Persons Who HaveVWD 39
Table 12. Clinical Results of DDAVP Treatment inPatients Who Have VWD 42
Table 13. Efficacy of VWF Replacement Concentratefor Surgery and Major Bleeding Events 44
Table 14. Suggested Durations of VWF Replacementfor Different Types of SurgicalProcedures 45
Table 15. Initial Dosing Recommendations for VWFConcentrate Replacement for Preventionor Management of Bleeding 45
Table 16. Effectiveness of Medical Therapy forMenorrhagia in Women Who HaveVWD 48
Table 17. Pregnancies in Women Who HaveVWD 51
iv von Willebrand Disease
7/31/2019 Von willbread.pdf
9/126
List of Figures
Figure 1. VWF and Normal Hemostasis 10
Figure 2. Structure and Domains of VWF 11
Figure 3. Initial Evaluation For VWD orOther Bleeding Disorders 20
Figure 4. Laboratory Assessment For VWD orOther Bleeding Disorders 25
Figure 5. Expected Laboratory Values in VWD 28
Figure 6. Analysis of VWF Multimers 29
vContents
7/31/2019 Von willbread.pdf
10/126
vi von Willebrand Disease
7/31/2019 Von willbread.pdf
11/126
Von Willebrand disease (VWD) is an inheritedbleeding disorder that is caused by deficiency ordysfunction of von Willebrand factor (VWF), aplasma protein that mediates the initial adhesion ofplatelets at sites of vascular injury and also binds andstabilizes blood clotting factor VIII (FVIII) in thecirculation. Therefore, defects in VWF can causebleeding by impairing platelet adhesion or by reducingthe concentration of FVIII.
VWD is a relatively common cause of bleeding, butthe prevalence varies considerably among studiesand depends strongly on the case definition that isused. VWD prevalence has been estimated in severalcountries on the basis of the number of symptomaticpatients seen at hemostasis centers, and the valuesrange from roughly 23 to 110 per million population(0.0023 to 0.01 percent).1
The prevalence of VWD also has been estimatedby screening populations to identify persons withbleeding symptoms, low VWF levels, and similarly
affected family members. This population-basedapproach has yielded estimates for VWD prevalenceof 0.6 percent,2 0.8 percent,3 and 1.3 percent4morethan two orders of magnitude higher than the valuesarrived at by surveys of hemostasis centers.
The discrepancies between the methods forestimating VWD prevalence illustrate the need forbetter information concerning the relationshipbetween VWF levels and bleeding. Many bleedingsymptoms are exacerbated by defects in VWF, butthe magnitude of the effect is not known. Forexample, approximately 12 percent of women who
have menstrual periods have excessive menstrualbleeding.5 This fraction is much higher amongwomen who have VWD, but it also appears to beincreased for women who have VWF levels at thelower end of the normal range. Quantitative data onthese issues would allow a more informed approachto the diagnosis and management of VWD and couldhave significant implications for medical practice andfor public health.
Aside from needs for better information about VWDprevalence and the relationship of low VWF levelsto bleeding symptoms or risk, there are needs forenhancing knowledge and improving clinical andlaboratory diagnostic tools for VWD. Furthermore,there are needs for better knowledge of and treatmentoptions for management of VWD and bleeding orbleeding risk. As documented in this VWD guidelinespublication, a relative paucity of published studies isavailable to support some of the recommendationswhich, therefore, are mainly based on Expert Panelopinion.
Guidelines for VWD diagnosis and management,based on the evidence from published studies and/or the opinions of experts, have been published forpractitioners in Canada,6 Italy,7 and the UnitedKingdom,8,9 but not in the United States. The VWDguidelines from the U.S. Expert Panel are based onreview of published evidence as well as expert opin-ion. Users of these guidelines should be aware thatindividual professional judgment is not abrogated
by recommendations in these guidelines.
These guidelines for diagnosis and management ofVWD were developed for practicing primary careand specialist cliniciansincluding family physicians,internists, obstetrician-gynecologists, pediatricians,and nurse-practitionersas well as hematologistsand laboratory medicine specialists.
History of This Project
During the spring of 2004, the National Heart, Lung,and Blood Institute (NHLBI) began planning for thedevelopment of clinical practice guidelines for VWDin response to the FY 2004 appropriations conferencecommittee report (House Report 108-401) recom-mendation. In that report, the conferees urgedNHLBI to develop a set of treatment guidelines forVWD and to work with medical associations andexperts in the field when developing such guidelines.
1Introduction
Introduction
7/31/2019 Von willbread.pdf
12/126
In consultation with the American Society ofHematology (ASH), the Institute convened an ExpertPanel on VWD, chaired by Dr. William Nichols ofthe Mayo Clinic, Rochester, MN. The Expert Panelmembers were selected to provide expertise inbasic sciences, clinical and laboratory diagnosis,
evidence-based medicine, and the clinical manage-ment of VWD, including specialists in hematology aswell as in family medicine, obstetrics and gynecology,pediatrics, internal medicine, and laboratory sciences.The Expert Panel comprised one basic scientist andnine physiciansincluding one family physician,one obstetrician and gynecologist, and sevenhematologists with expertise in VWD (two werepediatric hematologists). Ad hoc members of thePanel represented the Division of Blood Diseasesand Resources of the NHLBI. The Panel wascoordinated by the Division for the Application of
Research Discoveries (DARD), formerly the Officeof Prevention, Education, and Control of the NHLBI.Panel members disclosed, verbally and in writing, anyfinancial conflicts. (See page i for the financial andother disclosure summaries.)
Charge to the Panel
Dr. Barbara Alving, then Acting Director of theNHLBI, gave the charge to the Expert Panel toexamine the current science in the area of VWD
and to come to consensus regarding clinicalrecommendations for diagnosis, treatment, andmanagement of this common inherited bleedingdisorder. The Panel was also charged to base eachrecommendation on the current science and toindicate the strength of the relevant literature foreach recommendation.
The development of this report was entirely fundedby the NHLBI, National Institutes of Health (NIH).Panel members and reviewers participated as volun-teers and were reimbursed only for travel expensesrelated to the three in-person Expert Panel meetings.
Panel Assignments
After the Expert Panel finalized a basic outline forthe guidelines, members were assigned to the threesections: (1) Introduction and Background, (2)Diagnosis and Evaluation, and (3) Managementof VWD. Three members were assigned lead
responsibility for a particular section. The sectiongroups were responsible for developing detailedoutlines for the sections, reviewing the pertinentliterature, writing the sections, and draftingrecommendations with the supporting evidencefor the full Panel to review.
Literature Searches
Three section outlines, approved by the ExpertPanel chair, were used as the basis for compilingrelevant search terms, using the Medical SubjectHeadings (MeSH terms) of the MEDLINE database.If appropriate terms were not available in MeSH,then relevant non-MeSH keywords were used. Inaddition to the search terms, inclusion and exclusioncriteria were defined based on feedback from the
Panel about specific limits to include in the searchstrategies, specifically:
Date restriction: 19902004
Language: English
Study/publication types: randomized-controlledtrial; meta-analysis; controlled clinical trial;epidemiologic studies; prospective studies; multi-center study; clinical trial; evaluation studies;practice guideline; review, academic; review,multicase; technical report; validation studies;review of reported cases; case reports; journalarticle (to exclude letters, editorials, news, etc.)
The search strategies were constructed and executedin the MEDLINE database as well as in the CochraneDatabase of Systematic Reviews to compile a setof citations and abstracts for each section. Initialsearches on specific keyword combinations and dateand language limits were further refined by using thepublication type limits to produce results that moreclosely matched the section outlines. Once thesection results were compiled, the results were putin priority order by study type as follows:
1. Randomized-controlled trial
2. Meta-analysis (quantitative summary combiningresults of independent studies)
3. Controlled clinical trial
4. Multicenter study
5. Clinical trial (includes all types and phases ofclinical trials)
2 von Willebrand Disease
7/31/2019 Von willbread.pdf
13/126
6. Evaluation studies
7. Practice guideline (for specific health careguidelines)
8. Epidemiological
9. Prospective studies10. Review, academic (comprehensive, critical, or
analytical review)
11. Review, multicase (review with epidemiologicalapplications)
12. Technical report
13. Validation studies
14. Review of reported cases (review of known casesof a disease)
15. Case reports
Upon examination of the yield of the initial literaturesearch, it was determined that important areas in thesection outlines were not addressed by the citations,possibly due to the date exclusions. In addition,Panel members identified pertinent references fromtheir own searches and databases, including landmarkreferences predating the 1990 date restriction, and2005 and 2006 references (to October 2006).Therefore, as a followup, additional databasesearching was done using the same search strategiesfrom the initial round, but covering dates prior to1990 and during 2005 and 2006 to double check forkey studies appearing in the literature outside thelimits of the original range of dates. Also, refinedsearches in the 19902006 date range were conductedto analyze the references used by Panel members thathad not appeared in the original search results.
These revised searches helped round out the databasesearch to provide the most comprehensive approachpossible. As a result, the references used in the guide-lines included those retrieved from the two literaturesearches combined with the references suggested by
the Panel members. These references inform theguidelines and clinical recommendations, based onthe best available evidence in combination with thePanels expertise and consensus.
Clinical RecommendationsGrading andLevels of Evidence
Recommendations made in this document are basedon the levels of evidence described in Table 1, witha priority grading system of A, B, or C. Grade A is
reserved for recommendations based on evidencelevels Ia and Ib. Grade B is given for recommenda-tions having evidence levels of IIa, IIb, and III; andGrade C is for recommendations based on evidencelevel IV.8 None of the recommendations merited aGrade of A. Evidence tables are provided at the endof the document for those recommendations that aregraded as B and have two or more references (seepages 83111).
3Introduction
Table 1 . Level of Evidence
Ia Evidence obtained from meta-analysis ofrandomized-controlled trials
Ib Evidence obtained from at least onerandomized-controlled trial
IIa Evidence obtained from at least one well-designed controlled study withoutrandomization
IIb Evidence obtained from at least one othertype of well-designed quasi-experimentalstudy
III Evidence obtained from well-designed non-experimental descriptive studies, such ascomparative studies, correlation studies,and case-control studies
IV Evidence obtained from expert committeereports or opinions and/or clinicalexperiences of respected authorities
Source: Acute pain management: operative or medical procedures
and trauma. (Clinical practice guideline). Publication No. AHCPR920032. Rockville, MD: Agency for Health Care Policy and Research,
Public Health Service, U.S. Department of Health and Human Services,
February 1992.
Level Type of Evidence
7/31/2019 Von willbread.pdf
14/126
External and Internal Review
The NHLBI sought outside review of the guidelinesthrough a two-fold process. The followingGovernment agencies and professional organizationswere invited to review the draft document and
submit comments: Centers for Disease Controland Prevention, Food and Drug Administration,American Academy of Family Physicians, AmericanCollege of Obstetricians and Gynecologists,American College of Physicians, American Societyof Hematology, American Society of PediatricHematology/Oncology, College of AmericanPathologists, Hemophilia & Thrombosis ResearchSociety, National Hemophilia Foundation Medicaland Scientific Advisory Committee, and the NorthAmerican Specialized Coagulation LaboratoryAssociation. In addition, the guidelines were posted
on the NHLBI Web site for public review and com-ment during a 30-day period ending September 22,2006. Comments from the external review were com-piled and given to the full Panel for review and con-sensus. Revisions to the document were then madeas appropriate. The final draft, after Panel approval,was sent through review within the NIH and finallyapproved for publication by the NHLBI Director.
4 von Willebrand Disease
7/31/2019 Von willbread.pdf
15/126
Discovery and Identification of VWD/VWF
The patient who led to the discovery of a hereditarybleeding disorder that we now call VWD was a5-year-old girl who lived on the land Islandsand was brought to Deaconess Hospital in Helsinki,Finland, in 1924 to be seen by Dr. Erik vonWillebrand.10 He ultimately assessed 66 membersof her family and reported in 1926 that this wasa previously undescribed bleeding disorder that
differed from hemophilia and exhibited(1) mucocutaneous bleeding, (2) autosomalinheritance rather than being linked to the Xchromosome, (3) prolonged bleeding times bythe Duke method (ear lobe bleeding time), and(4) normal clotting time. Not only did herecognize the autosomal inheritance pattern, buthe recognized that bleeding symptoms were greaterin children and in women of childbearing age. Hesubsequently found that blood transfusions wereuseful not only to correct the anemia but also tocontrol bleeding.
In the 1950s, it became clear that a plasma factor,antihemophilic factor (FVIII), was decreased inthese persons and that Cohn fraction I-0 couldcorrect both the plasma deficiency of FVIII andthe prolonged bleeding time. For the first time,the factor causing the long bleeding time was calledvon Willebrand factor. As cryoprecipitate andcommercial FVIII concentrates were developed, itwas recognized that both VWF and antihemophilicfactor (FVIII) purified together.
When immunoassays were developed, persons whohad VWD (in contrast to those who had hemophiliaA) were found to have reduced factor VIII-relatedantigen (FVIIIR:Ag), which we now refer to asVWF:Ag. Characterization of the proteins revealedthat FVIII was the clotting protein deficient inhemophilia A, and VWF was a separate FVIII carrierprotein that resulted in the cofractionation of bothproteins in commercial concentrates. Furthermore,a deficiency of VWF resulted in increased FVIII
clearance because of the reduced carrier protein,VWF.
Since the 1980s, molecular and cellular studies havedefined hemophilia A and VWD more precisely.Persons who had VWD had a normal FVIII gene onthe X chromosome, and some were found to have anabnormal VWF gene on chromosome 12. Variantforms of VWF were recognized in the 1970s, and wenow recognize that these variations are the result of
synthesis of an abnormal protein. Gene sequencingidentified many of these persons as having a VWFgene mutation. The genetic causes of milder formsof low VWF are still under investigation, and theseforms may not always be caused by an abnormalVWF gene. In addition, there are acquired disordersthat may result in reduced or dysfunctional VWF(see section on Acquired von Willebrand Syndrome[AVWS]). Table 2 contains a synopsis of VWFdesignations, functions, and assays. Table 3 containsabbreviations used throughout this document.
The VWF Protein and Its Functions In Vivo
VWF is synthesized in two cell types. In the vascularendothelium, VWF is synthesized and subsequentlystored in secretory granules (Weibel-Palade bodies)from which it can be released by stress or drugs suchas desmopressin (DDAVP, 1-desamino-8-D-argininevasopressin), a synthetic analog of vasopressin. VWFis also synthesized in bone marrow megakaryocyteswhere it is stored in platelet alpha-granules fromwhich it is released following platelet activation.
DDAVP does not release platelet VWF.VWF is a protein that is assembled from identicalsubunits into linear strings of varying size referred toas multimers. These multimers can be >20 milliondaltons in mass and >2 micrometers in length. Thecomplex cellular processing consists of dimerizationin the endoplasmic reticulum (ER), glycosylation inthe ER and Golgi, multimerization in the Golgi, andpackaging into storage granules. The latter two
5Scientific Overview
Scientific Overview
7/31/2019 Von willbread.pdf
16/126
processes are under the control of the VWF propeptide(VWFpp), which is cleaved from VWF at the timeof storage. VWF that is released acutely intothe circulation is accompanied by a parallel rise inFVIII, but it is still not entirely clear whether thisproteinprotein association first occurs within theendothelial cell.11,12
In plasma, the FVIIIVWF complex circulates as aloosely coiled protein complex that does not interactstrongly with platelets or endothelial cells under basal
conditions. When vascular injury occurs, VWFbecomes tethered to the exposed subendothelium(collagen, etc.). The high fluid shear rates that occurin the microcirculation appear to induce a conforma-tional change in multimeric VWF that causes plateletsto adhere, become activated, and then aggregate so asto present an activated platelet phospholipid surface.This facilitates clotting that is, in part, regulated byFVIII. Because of the specific characteristics of
hemostasis and fibrinolysis on mucosal surfaces,symptoms in VWD are often greater in these tissues.
Plasma VWF is primarily derived from endothelialsynthesis. Platelet and endothelial cell VWF arereleased locally following cellular activation wherethis VWF participates in the developing hemostaticplug or thrombus (see Figure 1 on page 10).
Plasma VWF has a half-life of approximately 12hours (range 915 hours). VWF is present as very
large multimers that are subjected to physiologicdegradation by the metalloprotease ADAMTS13 (ADisintegrin-like And Metalloprotease domain [repro-lysin type] with Thrombospondin type I motifs).Deficiency of ADAMTS13 is associated with thepathologic microangiopathy of thrombotic thrombo-cytopenic purpura (TTP). The most common vari-ant forms of type 2A VWD are characterized byincreased VWF susceptibility to ADAMTS13.
6 von Willebrand Disease
Designation
von Willebrand factor (VWF)
von Willebrand factor ristocetincofactor activity (VWF:RCo)
von Willebrand factor antigen(VWF:Ag)
von Willebrand factorcollagen-binding activity(VWF:CB)
von Willebrand factor multimers
Factor VIII (FVIII)
Ristocetin-induced PlateletAggregation (RIPA)
Property
Multimeric glycoprotein that promotesplatelet adhesion and aggregation andis a carrier for FVIII in plasma
Binding activity of VWF that causesbinding of VWF to platelets in thepresence of ristocetin with consequentagglutination
VWF protein as measured by proteinassays; does not imply functional ability
Ability of VWF to bind to collagen
Size distribution of VWF multimers asassessed by agarose gel electrophoresis
Circulating coagulation protein that isprotected from clearance by VWF andis important in thrombin generation
Test that measures the ability of apersons VWF to bind to platelets inthe presence of various concentrationsof ristocetin
Assay
See specific VWF assays below
Ristocetin cofactor activity: quantitatesplatelet agglutination after addition ofristocetin and VWF
Immunologic assays such as ELISA*,LIA*, RIA*, Laurell electroimmunoassay
Collagen-binding activity: quantitatesbinding of VWF to collagen-coatedELISA* plates
VWF multimer assay: electrophoresisin agarose gel and visualization bymonospecific antibody to VWF
FVIII activity: plasma clotting test basedon PTT* assay using FVIII-deficientsubstrate; quantitates activity
RIPA: aggregation of a persons PRP* tovarious concentrations of ristocetin
Table 2. Synopsis of VWF Designations, Propert ies, and Assays
*See Table 3. Nomenclature and Abbreviations.
7/31/2019 Von willbread.pdf
17/126
7Scientific Overview
Designation Definition
ADAMTS13 A Disintegrin-like And Metalloprotease domain (reprolysin type) with ThromboSpondintype 1 motifs, a plasma metalloprotease that cleaves multimeric VWF
ASH American Society of HematologyAVWS acquired von Willebrand syndrome
BT bleeding time
CAP College of American Pathologists
CBC complete blood count
CDC Centers for Disease Control and Prevention
CFC clotting factor concentrate
CI confidence interval
C.I. continuous infusion
CLSI Clinical Laboratory Standards Institute (formerly National Committee for ClinicalLaboratory Standards: NCCLS)
CNS central nervous system
CV coefficient of variation
Cyclic AMP adenosine 35cyclic phosphate
CK cystine knot
D & C dilation and curettage
DARD Division for the Application of Research Discoveries
DDAVP 1-desamino-8-D-arginine vasopressin (desmopressin, a synthetic analog of vasopressin)
DIC disseminated intravascular coagulation
DNA deoxyribonucleic acid
DVT deep vein thrombosis
ELISA enzyme-linked immunosorbent assay
ER endoplasmic reticulum
FDA Food and Drug Administration
FFP fresh frozen plasma
FVIII* [blood clotting] factor VIII
FVIIIR:Ag* factor VIII-related antigen (see VWF:Ag)
FVIII:C* factor VIII coagulant activity
FVIII gene factor VIII gene
GI gastrointestinal
Table 3. Nomenclature and Abbreviat ions
7/31/2019 Von willbread.pdf
18/126
8 von Willebrand Disease
Designation Definition
Table 3. Nomenclature and Abbreviat ions (cont inued)
GPIb glycoprotein Ib (platelet)
GPIIb/IIIa glycoprotein IIb/IIIa complex (platelet)
HRT hormone replacement therapy
IgG immunoglobulin G
IGIV immune globulin intravenous (also known as IVIG)
ISTH International Society on Thrombosis and Haemostasis
IU/dL international units per deciliter
LIA latex immunoassay (automated)
MAB monoclonal antibody
MeSH medical subject headings (in MEDLINE)MGUS monoclonal gammopathy of uncertain significance
NCCLS National Committee for Clinical Laboratory Standards
NHF, MASAC National Hemophilia Foundation, Medical and Scientific Advisory Committee
NHLBI National Heart, Lung, and Blood Institute
NIH National Institutes of Health
N.R. not reported
NSAIDs nonsteroidal anti-inflammatory drugs
OCP oral contraceptive pill
PAI-1 plasminogen activator inhibitor type 1
PCR polymerase chain reaction
PFA-100 platelet function analyzer
PLT-VWD platelet-type von Willebrand disease
PRP platelet-rich plasma
PT prothrombin time
PTT partial thromboplastin time (activated partial thromboplastin time)
RIA radioimmunoassay
RIPA ristocetin-induced platelet aggregation
SDS sodium dodecyl sulfate
TTP thrombotic thrombocytopenic purpura
tPA tissue plasminogen activator
TT thrombin time
Tx treatment
7/31/2019 Von willbread.pdf
19/126
Factors that affect levels of plasma VWFinclude age,race, ABO and Lewis blood groups, epinephrine,inflammatory mediators, and endocrine hormones
(particularly those associated with the menstrualcycle and pregnancy). VWF is increased duringpregnancy (a three- to fivefold elevation over thewomans baseline by the third trimester), with aging,and with acute stress or inflammation. Africans andAfrican Americans have higher average levels of VWFthan the Caucasian population.13,14 VWF is reducedby hypothyroidism and rarely by autoantibodies toVWF. The rate of VWF synthesis probably is notaffected by blood group; however, the survival ofVWF appears to be reduced in individuals who havetype O blood. In fact, ABO blood group substancehas been identified on VWF.
The Genetics of VWD
Since the 1980s, molecular and cellular studies havedefined hemophilia A and VWD more precisely.Persons who have severe VWD have a normal FVIIIgene on the X chromosome, and some are found to
have an abnormal VWF gene on chromosome 12.The VWF gene is located near the tip of the shortarm of chromosome 12, at 12p13.3.15 It spans
approximately 178 kb of DNA and contains 52exons.16 Intronexon boundaries tend to delimitstructural domains in the protein, and introns oftenoccur at similar positions within the gene segmentsthat encode homologous domains. Thus, thestructure of the VWF gene reflects the mosaic natureof the protein (Figure 2).
A partial, unprocessed VWF pseudogene is locatedat chromosome 22q11.2.17 This pseudogene spansapproximately 25 kb of DNA and corresponds toexons 2334 and part of the adjacent introns of the
VWF gene.18 This segment of the gene encodesdomains A1A2A3, which contain binding sites forplatelet glycoprotein Ib (GPIb) and collagen, aswell as the site cleaved by ADAMTS13. The VWFpseudogene and gene have diverged 3.1 percentin DNA sequence, consistent with a relativelyrecent origin of the pseudogene by partial geneduplication.18 This pseudogene is found inhumans and great apes (bonobo, chimpanzee,
9Scientific Overview
Designation Definition
Table 3. Nomenclature and Abbreviat ions (cont inued)
VWD von Willebrand disease
VWF* von Willebrand factor (FVIII carrier protein)
VWF:Ac von Willebrand factor activity
VWF:Ag* von Willebrand factor antigen
VWF:CB* von Willebrand factor collagen-binding activity
VWF:FVIIIB* von Willebrand factor: factor VIII binding assay
VWF gene von Willebrand factor gene
VWF:PB assay von Willebrand factor platelet-binding assay
VWFpp von Willebrand factor propeptide
VWF:RCo* von Willebrand factor ristocetin cofactor activityWHO World Health Organization
*These abbreviations (for FVIII and VWF and all their properties) are defined in Marder VJ, Mannucci PM, Firkin BG, Hoyer LW, Meyer D.
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and
Haemostasis. Thromb Haemost1985 Dec;54(4):871872; Mazurier C, Rodeghiero F. Recommended abbreviations for von Willebrand Factor
and its activities. Thromb Haemost 2001 Aug;86(2):712.
7/31/2019 Von willbread.pdf
20/126
10 von Willebrand Disease
gorilla, orangutan) but not in more distantly relatedprimates.19 The VWF pseudogene complicatesthe detection of VWF gene mutations becausepolymerase chain reactions (PCRs) can inadvertently
amplify segments from either or both loci, but thisdifficulty can be overcome by careful design ofgene-specific PCR primers.18
The VWF pseudogene may occasionally serve as areservoir of mutations that can be introduced intothe VWF locus. For example, some silent and somepotentially pathogenic mutations have been identifiedin exons 27 and 28 of the VWF gene of personswho have VWD. These same sequence variations
occur consecutively in the VWF pseudogene andmight have been transferred to the VWF by geneconversion.2022 The segments involved in thepotential gene conversion events are relatively short,
from a minimum of 7 nucleotides20 to a maximum of385 nucleotides.22 The frequency of these potentialinterchromosomal exchanges is unknown.
The spectrum of VWF gene mutations that causeVWD is similar to that of many other human geneticdiseases and includes large deletions, frameshifts fromsmall insertions or deletions, splice-site mutations,nonsense mutations causing premature terminationof translation, and missense mutations affecting
A cross-sectioned blood vessel shows stages of hemostasis. Top, VWF is the carrier protein for blood clotting factor VIII (FVIII). Under normal
conditions VWF does not interact with platelets or the blood vessel wall that is covered with endothelial cells. Middle left, following vascularinjury, VWF adheres to the exposed subendothelial matrix. Middle right, after VWF is uncoiled by local shear forces, platelets adhere to thealtered VWF and these platelets undergo activation and recruit other platelets to this injury site. Bottom left, the activated and aggregated
platelets alter their membrane phospholipids exposing phosphatidylserine, and this activated platelet surface binds clotting factors from
circulating blood and initiates blood clotting on this surface where fibrin is locally deposited. Bottom right, the combination of clotting and
platelet aggregation and adhesion forms a platelet-fibrin plug, which results in the cessation of bleeding. The extent of the clotting is carefully
regulated by natural anticoagulants. Subsequently, thrombolysis initiates tissue repair and ultimately the vessel may be re-endothelialized and
blood flow maintained.Note: Used by permission of R.R. Montgomery.
F igure 1 . VWF and Normal Hemostasis
7/31/2019 Von willbread.pdf
21/126
single amino acid residues. A database of VWFmutations and polymorphisms has been compiledfor the International Society on Thrombosis andHaemostasis (ISTH)23,24 and is maintained for onlineaccess at the University of Sheffield (http://www.shef.ac.uk/vwf/index.html). Mutations causing VWDhave been identified throughout the VWF gene.In contrast to hemophilia A, in which a single major
gene rearrangement causes a large fraction of severedisease, no such recurring mutation is commonin VWD. There is a good correlation between thelocation of mutations in the VWF gene and thesubtype of VWD, as discussed in more detail inClassification of VWD Subtypes. In selectedfamilies, this information can facilitate the searchfor VWF mutations by DNA sequencing.
Classification of VWD Subtypes
VWD is classified on the basis of criteria developedby the VWF Subcommittee of the ISTH, firstpublished in 1994 and revised in 2006 (Table 4).25,26
The classification was intended to be clinicallyrelevant to the treatment of VWD. Diagnosticcategories were defined that encompassed distinct
pathophysiologic mechanisms and correlated withthe response to treatment with DDAVP or bloodproducts. The classification was designed to beconceptually independent of specific laboratorytesting procedures, although most of the VWDsubtypes could be assigned by using tests that werewidely available. The 1994 classification reservedthe designation of VWD for disorders caused bymutations within the VWF gene,25 but this criterion
11Scientific Overview
The von Willebrand factor (VWF) protein sequence (amino acid 12813) is aligned with the cDNA sequence (nucleic acid 18439). The VWF
signal peptide is the first 22 aa, the propeptide (VWFpp) aa 23763, and mature VWF aa 7642800. Type 2 mutations are primarily located in
specific domains (regions) along the VWF protein. Types 2A, 2B, and 2M VWF mutations are primarily located within exon 28 that encodes for
the A1 and A2 domains of VWF. The two different types of 2A are those that have increased proteolysis (2A2) and those with abnormal multi-mer synthesis (2A1). Type 2N mutations are located within the D and D3 domains. Ligands that bind to certain VWF domains are identified,
including FVIII, heparin, GPIb (platelet glycoprotein Ib complex), collagen, and GPIIb/IIIa (platelet glycoprotein IIb/IIIa complex that binds to theRGD [arginine-glycine-aspartate] amino acid sequence in VWF).
Note: Used by permission of R.R. Montgomery.
F igure 2. Structure and Domains of VWF
7/31/2019 Von willbread.pdf
22/126
has been dropped from the 2006 classification26
because in practice it is verifiable for only a smallfraction of patients.
VWD is classified into three major categories: partialquantitative deficiency (type 1), qualitative deficiency
(type 2), and total deficiency (type 3). Type 2 VWDis divided further into four variants (2A, 2B, 2M, 2N)on the basis of details of the phenotype. Before thepublication of the 1994 revised classification ofVWD,25 VWD subtypes were classified using Romannumerals (types I, II, and III), generally correspondingto types 1, 2, and 3 in the 1994 classification, andwithin type II several subtypes existed (designatedby adding sequential letters of the alphabet; i.e.,II-A through II-I). Most of the latter VWD variantswere amalgamated as type 2A in the 1994 classifica-tion, with the exception of type 2B (formerly II-B)
for which a separate new classification was created.In addition, a new subtype (2M) was created toinclude variants with decreased platelet dependentfunction (VWF:RCo) but no significant decrease ofhigher molecular weight VWF multimers (which mayor may not have other aberrant structure), with Mrepresenting multimer. Subtype 2N VWD wasdefined, with N representing Normandy wherethe first individuals were identified, with decreasedFVIII due to VWF defects of FVIII binding.
Type 1 VWD affects approximately 75 percentof symptomatic persons who have VWD (seeCastaman et al., 2003 for a review).27 Almost all ofthe remaining persons are divided among the four
12 von Willebrand Disease
Type
1
2
2A
2B
2M
2N
3
Description
Partial quantitative deficiency of VWF
Qualitative VWF defect
Decreased VWF-dependent plateletadhesion with selective deficiency ofhigh-molecular-weight multimers
Increased affinity for platelet GPIb
Decreased VWF-dependent plateletadhesion without selective deficiency ofhigh-molecular-weight multimers
Markedly decreased binding affinityfor FVIII
Virtually complete deficiency of VWF
Table 4. C lass i f i cat ion of VWD
Note: VWD types are defined as described in Sadler JE, Budde U,
Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA,
Lillicrap D, Mannucci PM, et al. Update on the pathophysiology and
classification of von Willebrand disease: a report of the
Subcommittee on von Willebrand Factor. J Thromb Haemost2006
Oct;4(10):21032114.
Type Inheritance Prevalence Bleeding Propensity
Type 1 Autosomal dominant Up to 1% Mild to moderate
Type 2A Autosomal dominant (or recessive) Uncommon Variableusually moderate
Type 2B Autosomal dominant Uncommon Variableusually moderate
Type 2M Autosomal dominant (or recessive) Uncommon Variableusually moderate
Type 2N Autosomal recessive Uncommon Variableusually moderate
Type 3 (Severe) Autosomal recessive Rare (1:250,000 to High (severe bleeding)1:1,000,000)
Table 5 . Inher i tance, Prevalence, and B leeding Propensi ty in Patients Who Have VWD
7/31/2019 Von willbread.pdf
23/126
type 2 variants, and the partitioning among themvaries considerably among centers. In France, forexample, patients distribution was reported to be30 percent type 2A, 28 percent type 2B, 8 percenttype 2M (or unclassified), and 34 percent type 2N.28
In Bonn, Germany, the distribution was reported to
be 74 percent type 2A, 10 percent type 2B, 13 percenttype 2M, and 3.5 percent type 2N.29 Table 5 summa-rizes information about inheritance, prevalence, andbleeding propensity in persons who have differenttypes of VWD.
The prevalence of type 3 VWD in the populationis not known precisely but has been estimated(per million population) as: 0.55 for Italy,30 1.38for North America,31 3.12 for Sweden,30 and 3.2for Israel.32 The prevalence may be as high as6 per million where consanguinity is common.1
Type 1 VWD
Type 1 VWD is found in persons who have partialquantitative deficiency of VWF. The level of VWFin plasma is low, and the remaining VWF mediatesplatelet adhesion normally and binds FVIII normally.Laboratory evaluation shows concordant decreases inVWF protein concentration (VWF:Ag) and assays ofVWF function (VWF:RCo). Levels of blood clottingFVIII usually parallel VWF and may be reducedsecondary to reduced VWF. Usually, in type 1 VWD,the FVIII/VWF:Ag ratio is 1.52.0. In most persons
who have type 1 VWD, this results in FVIII beingnormal, or mildly decreased, and not reduced asmuch as the VWF. VWF multimer gels show nosignificant decrease in large VWF multimers.25 Thelaboratory evaluation of VWD is discussed in theDiagnosis and Evaluation section.
The spectrum of mutations occurring in VWDtype 1 has been described extensively in two majorstudies.33,34 Particularly severe, highly penetrantforms of type 1 VWD may be caused by dominantVWF mutations that interfere with the intracellulartransport of dimeric proVWF35-39 or that promote therapid clearance of VWF from the circulation.38,40,41
Persons who have such mutations usually have VWFlevels
7/31/2019 Von willbread.pdf
24/126
The location of type 2A VWD mutations sometimescan be inferred from high-resolution VWF multimergels. For example, mutations that primarily reducemultimer assembly lead to the secretion of multimersthat are too small to engage platelets effectivelyand therefore are relatively resistant to proteolysis
by ADAMTS13. Homozygous mutations in thepropeptide impair multimer assembly in the Golgiand give rise to a characteristic clean pattern ofsmall multimers that lack the satellite bands usuallyassociated with proteolysis (see Diagnosis andEvaluation); this pattern was initially describedas type IIC VWD.5052 Heterozygous mutationsin the cystine knot (CK) domain can impairdimerization of proVWF in the ER and cause arecognizable multimer pattern originally referredto as type IID.53,54 A mixture of monomers anddimers arrives in the Golgi, where the incorporation
of monomers at the end of a multimer preventsfurther elongation. As a result, the secreted smallmultimers contain minor species with an oddnumber of subunits that appear as faint bandsbetween the usual species that contain an evennumber of subunits. Heterozygous mutations incysteine residues of the D3 domain also can impairmultimer assembly, but these mutations often alsoproduce an indistinct or smeary multimer patternreferred to as type IIE.55,56
In contrast to mutations that primarily affect
multimer assembly, mutations within or near theA2 domain of VWF cause type 2A VWD that isassociated with markedly increased proteolysis ofthe VWF subunits56 (see Figure 2, on page 11). Thesemutations apparently interfere with the folding of theA2 domain and make the Tyr1605Met1606 bondaccessible to ADAMTS13 even in the absence ofincreased fluid shear stress. Two subgroups of thispattern have been distinguished: group I mutationsenhance proteolysis by ADAMTS13 and also impairmultimer assembly, whereas group II mutationsenhance proteolysis without decreasing the assembly
of large VWF multimers.49 Computer modeling ofdomain A2 suggests that group I mutations affectboth assembly and proteolysis, because group Imutations have a more disruptive effect on thefolding of domain A2 than do group II mutations.57
Type 2B VWDis caused by mutations that pathologi-cally increase plateletVWF binding, which leads tothe proteolytic degradation and depletion of large,functional VWF multimers.56,58 Circulating platelets
also are coated with mutant VWF, which may preventthe platelets from adhering at sites of injury.59
Although laboratory results for type 2B VWD maybe similar to those in type 2A or type 2M VWD,patients who have type 2B VWD typically have
thrombocytopenia that is exacerbated by surgery,pregnancy, or other stress.6062 The thrombocytope-nia probably is caused by reversible sequestration ofVWFplatelet aggregates in the microcirculation.These aggregates are dissolved by the action ofADAMTS13 on VWF, causing the characteristicdecrease of large VWF multimers and the prominentsatellite banding pattern that indicates increasedproteolytic degradation.63,64 The diagnosis of type 2BVWD depends on finding abnormally increasedristocetin induced platelet aggregation (RIPA) at lowconcentrations of ristocetin.
Type 2B VWD mutations occur within or adjacent toVWF domain A1,23,55,6568 which changes conforma-tion when it binds to platelet GPIb.69 The mutationsappear to enhance platelet binding by stabilizing thebound conformation of domain A1.
Type 2M VWDincludes variants with decreasedVWF-dependent platelet adhesion that is not causedby the absence of high-molecular-weight VWFmultimers. Instead, type 2M VWD mutations reducethe interaction of VWF with platelet GPIb or withconnective tissue and do not substantially impair
multimer assembly. Screening laboratory results intype 2M VWD and type 2A VWD are similar, and thedistinction between them depends on multimer gelelectrophoresis.67
Mutations in type 2M VWD have been identifiedin domain A1 (see Figure 2 on page 11), where theyinterfere with binding to platelet GPIb.23,55,67,7072
One family has been reported in which a mutation inVWF domain A3 reduces VWF binding to collagen,thereby reducing platelet adhesion and possiblycausing type 2M VWD.73
Type 2N VWDis caused by VWF mutations thatimpair binding to FVIII, lowering FVIII levels so thattype 2N VWD masquerades as an autosomal recessiveform of hemophilia A.7476 In typical cases, the FVIIIlevel is less than 10 percent, with a normal VWF:Agand VWF:RCo. Discrimination from hemophilia Amay require assays of FVIIIVWF binding.77,78
Most mutations that cause type 2N VWD occurwithin the FVIII binding site of VWF (see Figure 2
14 von Willebrand Disease
7/31/2019 Von willbread.pdf
25/126
on page 11), which lies between residues Ser764 andArg1035 and spans domain D and part of domainD3.23,79,80 The most common mutation, Arg854Gln,has a relatively mild effect on FVIII binding and tendsto cause a less severe type 2N VWD phenotype.77
Some mutations in the D3 domain C-terminal of
Arg1035 can reduce FVIII binding,8183 presumablythrough an indirect effect on the structure or accessi-bility of the binding site.
Type 3 VWD
Type 3 VWD is characterized by undetectable VWFprotein and activity, and FVIII levels usually arevery low (19 IU/dL).8486 Nonsense and frameshiftmutations commonly cause type 3 VWD, althoughlarge deletions, splice-site mutations, and missensemutations also can do so. Mutations are distributed
throughout the VWF gene, and most are unique tothe family in which they were first identified.23,87,88
A small fraction of patients who have type 3 VWDdevelop alloantibodies to VWF in response to thetransfusion of plasma products. These antibodieshave been reported in 2.69.5 percent of patients whohave type 3 VWD, as determined by physician surveysor screening.85,89 The true incidence is uncertain,however, because of unavoidable selection bias inthese studies. Anti-VWF alloantibodies can inhibitthe hemostatic effect of blood-product therapy and
also may cause life-threatening allergic reactions.85,90Large deletions in the VWF gene may predisposepatients to this complication.89
VWD Classification, General Issues
The principal difficulties in using the current VWDclassification concern how to define the boundariesbetween the various subtypes through laboratorytesting. In addition, some mutations have pleiotropiceffects on VWF structure and function, and somepersons are compound heterozygous for mutationsthat cause VWD by different mechanisms. This
heterogeneity can produce complex phenotypesthat are difficult to categorize. Clinical studies ofthe relationship between VWD genotype andclinical phenotype would be helpful to improve themanagement of patients with the different subtypesof VWD.
The distinction between quantitative (type 1) andqualitative (type 2) defects depends on the ability
to recognize discrepancies among VWF assayresults,80,91 as discussed in Diagnosis andEvaluation. Similarly, distinguishing between type2A and type 2M VWD requires multimer gel analysis.Standards need to be established for using laboratorytests to make these important distinctions.
The example of Vicenza VWD illustrates some ofthese problems. Vicenza VWD was first described asa variant of VWD in which the level of plasma VWFis usually
7/31/2019 Von willbread.pdf
26/126
On the other hand, VWF levels of 3050 IU/dL, justbelow the usual normal range (50200 IU/dL), poseproblems for diagnosis and treatment. Among thetotal U.S. population of approximately 300 million,VWF levels
7/31/2019 Von willbread.pdf
27/126
An effect of the VWF locus has been difficult todiscern by linkage analysis. One study suggestedthat 20 percent of the variance in VWF levels isattributable to the VWF gene,108 whereas anotherstudy could not demonstrate such a relationship.110
In sum, known genetic factors account for a minorityof the heritable variation in VWF level, and moder-ately low VWF levels (3050 IU/dL) do not showconsistent linkage to the VWF locus.97,98,100,101 Thediagnosis and management of VWD would befacilitated by better knowledge of how inheritedand environmental factors influence the plasmaconcentration of VWF.
The attribution of bleeding to a low VWF level canbe difficult because mild bleeding symptoms are verycommon, as discussed in the section on Diagnosisand Evaluation, and the risk of bleeding is only
modestly increased for persons who have moderatelydecreased VWF levels.45 For example, in the course ofinvestigating patients who have type 3 VWD, approxi-mately 190 obligate heterozygous relatives have hadbleeding histories obtained and VWF levels measured(see Table 6). The geometric mean VWF level was47 IU/dL,45 with a range (2 SD) of 16140 IU/dL.Among 117 persons who had VWF 50 IU/dL, 10 (14 percent)had bleeding symptoms. Therefore, the relative riskof bleeding was 1.9 (P= 0.046, Fishers exact test) forpersons who had low VWF. There was a trend foran increased frequency of bleeding symptoms atthe lowest VWF levels: among 31 persons who hadVWF levels 50 IU/dL.113
The management of bleeding associated with VWFdeficiency would be facilitated by better understand-ing of the heritability of low VWF levels (in the range
of 2050 IU/dL), their association with intragenicVWF mutations, and their interactions with othermodifiers of bleeding risk. Such data could providea foundation for treating VWF level as a biomarkerfor a moderate risk of bleeding, much as highblood pressure and high cholesterol are treated asbiomarkers for cardiovascular disease (CVD) risk.
Acquired von Willebrand Syndrome
Acquired von Willebrand syndrome (AVWS) refers todefects in VWF concentration, structure, or functionthat are not inherited directly but are consequencesof other medical disorders. Laboratory findings in
AVWS are similar to those in VWD and may includedecreased values for VWF:Ag, VWF:RCo, or FVIII.The VWF multimer distribution may be normal,but the distribution often shows a decrease in largemultimers similar to that seen in type 2A VWD.117,118
AVWS usually is caused by one of three mechanisms:autoimmune clearance or inhibition of VWF,increased shear-induced proteolysis of VWF, orincreased binding of VWF to platelets or other cellsurfaces. Autoimmune mechanisms may causeAVWS in association with lymphoproliferativediseases, monoclonal gammopathies, systemic lupus
erythematosis, other autoimmune disorders, andsome cancers. Autoantibodies to VWF have beendetected in less than 20 percent of patients in whomthey have been sought, suggesting that the methodsfor antibody detection may not be sufficientlysensitive or that AVWS in these settings may notalways have an autoimmune basis.
Pathologic increases in fluid shear stress can occurwith cardiovascular lesions, such as ventricularseptal defect and aortic stenosis, or with primarypulmonary hypertension. The increased shear stresscan increase the proteolysis of VWF by ADAMTS13enough to deplete large VWF multimers and therebyproduce a bleeding diathesis that resembles type 2AVWD. The VWF multimer distribution improves ifthe underlying cardiovascular condition is treatedsuccessfully.117122
Increased binding to cell surfaces, particularlyplatelets, also can consume large VWF multimers.An inverse relationship exists between the plateletcount and VWF multimer size, probably becauseincreased encounters with platelets promoteincreased cleavage of VWF by ADAMTS13. This
mechanism probably accounts for AVWS associatedwith myeloproliferative disorders; reduction of theplatelet count can restore a normal VWF multimerdistribution.123125 In rare instances, VWF has beenreported to bind GPIb that was expressed ectopicallyon tumor cells.118,126
AVWS has been described in hypothyroidism causedby nonimmune mechanism.127 Several drugs havebeen associated with AVWS; those most commonly
17Scientific Overview
7/31/2019 Von willbread.pdf
28/126
reported include valproic acid, ciprofloxacin,griseofulvin, and hydroxyethyl starch.117,118
AVWS occurs in a variety of conditions, but otherclinical features may direct attention away from thispotential cause of bleeding. More studies are needed
to determine the incidence of AVWS and to define itscontribution to bleeding in the many diseases andconditions with which it is associated.
Prothrombotic Clinical Issues and VWF in
Persons Who Do Not Have VWD
Whether elevation of VWF is prothrombotic has beenthe subject of several investigations. Both arterial andvenous thrombotic disorders have been studied.
Open-heart surgery. Hemostatic activation after
open-heart surgery has been suggested as amechanism of increased risk of postoperativethrombosis in this setting. A randomized trialcomparing coronary artery surgery with or withoutcardiopulmonary bypass (off-pump) found aconsistent and equivalent rise in VWF:Ag levelsat 14 postoperative days in the two groups,128
suggesting that the surgery itself, rather thancardiopulmonary bypass, was responsible for therise in VWF. There is no direct evidence that thepostoperative rise in VWF contributes to the riskof thrombosis after cardiac surgery.
Coronary artery disease. Three large prospectivestudies of subjects without evidence of ischemic heartdisease at entry have shown, by univariate analysis, asignificant association of VWF:Ag level at entry withsubsequent ischemic coronary events.129131 However,the association remained significant by multivariateanalysis in only one subset of subjects in thesestudies,129 a finding that could have occurred bychance. These findings suggest that the associationof VWF with incidence of coronary ischemic eventsis relatively weak and may not be directly causal.
Thrombosis associated with atrial fibrillation. Aprospective study of vascular events in subjectswith atrial fibrillation found, by univariate analysis,a significant association of VWF:Ag level withsubsequent stroke or vascular events. The associationwith vascular events remained significant withmultivariate analysis.132
Thrombotic thrombocytopenic purpura (TTP). Thehereditary deficiency or acquired inhibition of aVWF-cleaving protease, ADAMTS13, is associatedwith the survival in plasma of ultralarge VWFmultimers, which are involved in the propensityto development of platelet-rich thrombi in the
microvasculature of individuals who have TTP.133,134
Deep vein thrombosis (DVT). In a case-control studyof 301 patients, evaluated at least 3 months aftercessation of anticoagulation treatment for a firstepisode of DVT, plasma levels of VWF:Ag and FVIIIactivity were related to risk of DVT, according tounivariate analysis. In multivariate analysis, therelation of VWF level with risk of DVT was notsignificant after adjustment for FVIII levels.135
18 von Willebrand Disease
7/31/2019 Von willbread.pdf
29/126
19
Introduction
The evaluation of a person for possible VWD orother bleeding disorders may be initiated because ofa variety of clinical indications (see Figure 3). Theseindications and situations may include evaluation of:(1) an asymptomatic person who will undergo asurgical or interventional procedure; (2) personswho present with current symptoms of or a historyof increased bleeding, abnormal laboratory studies,
and/or a positive family history of a bleedingdisorder; or (3) persons who present with a priordiagnosis of VWD but do not have supportinglaboratory documentation. In all cases, the initialstep in assessment should focus on key aspects of thepersons clinical history to determine whether theperson may benefit from further diagnostic evaluation.This section is divided into two parts. The firstpart uses a summary of the medical literature toprovide suggested questions for an initial assessmentof persons presenting for concerns about bleedingissues or for evaluation prior to procedures that may
increase their risk of bleeding. Using the answers tothe initial assessment, the second part focuses on astrategy for optimal laboratory assessment of thosepersons who potentially have bleeding disorders andsuggests guidelines for interpretation of laboratoryresults.
Evaluation of the Patient
History, Signs, and Symptoms
The initial clinical assessment ofa person who isbeing evaluated for VWD should focus on a personalhistory of excessive bleeding throughout the personslife and any family history of a bleeding disorder. Thehistory of bleeding should identify the spontaneity andseverity, sites of bleeding, duration of bleeding, typeof insult or injury associated with bleeding, ease withwhich bleeding can be stopped, and concurrent med-icationssuch as aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel (Plavix),
warfarin, or heparinat the onset of bleeding.Particularly when an invasive procedure isanticipated, the person should be asked whether heor she is currently taking any of these medicationsand also whether he or she has any history of liveror kidney disease, blood or bone marrow disease,or high or low platelet counts. If a history of anyof these illnesses is present, further appropriateevaluation or referral should be undertaken.
Clinical manifestations. The most common present-ing symptoms in persons subsequently diagnosedwith VWD are summarized in Table 7. Symptomsusually involve mucous membranes and skin sites,and bleeding is of mild to moderate severity (bleedingthat does not require blood transfusions and usuallydoes not require visits to the physician) for mostpersons who have VWD, reflecting the predominanceof type 1 VWD. However, life-threatening bleeding(CNS, gastrointestinal) can occur in persons whohave type 3 VWD, in some persons who have type 2VWD, and rarely in persons who have type 1 VWD.
Uncommon bleeding manifestations, such ashemarthrosis, are more common in persons who havea more severe deficiency, especially those who havetype 3 VWD.85,136 Clinical symptoms may also bemodified by coexisting illnesses or other medications.For example, use of aspirin or other NSAIDs canexacerbate the bleeding tendency, whereas use oforal contraceptives can decrease bleeding in womenwho have VWD.
The clinical evaluation of bleeding symptoms is achallenge, because mild bleeding symptoms are
also very common in healthy populations (Table 7,shaded column). Responses to questionnaires usedto survey healthy controls indicate that they identifythemselves as having specific bleeding manifestationsas frequently as persons who have VWD, particularlytype 1 VWD (Table 7).137,138,140,143 In addition, afamily history of bleeding was reported by 44 percentof healthy children undergoing tonsillectomy143 andby 35 percent138 or 60 percent144 of persons referredbecause of bleeding. Because bleeding symptoms are
Diagnosis and Evaluation
Diagnosis and Evaluation
7/31/2019 Von willbread.pdf
30/126
20 von Willebrand Disease
so prevalent, it may be impossible to establish a
causal relationship between bleeding and low VWF.Some of the most important clinical issues in VWDapply specifically to women, particularly menorrhagia.Studies of women who have VWD report a highprevalence of menorrhagia (Table 7), although thedefinition of menorrhagia is not clearly specifiedin most of these studies and the diagnostic criteriafor VWD are not uniform. The sensitivity ofmenorrhagia as a predictor of VWD may be estimated
as 32100 percent. However, menorrhagia is a
common symptom, occurring with a similar frequencyin healthy controls and women who have VWD;therefore, it is not a specific marker for VWD (Table7). In a survey of 102 women who had VWD andwere registered at hemophilia treatment centers inthe United States, 95 percent reported a history ofmenorrhagia, but 61 percent of controls also reporteda history of menorrhagia.145 Studies have reported aprevalence of VWD of between 520 percent amongwomen who have menorrhagia.146152 Therefore, the
Questions to Patient History From Patient
1. Have you or a blood relative ever needed medical attention for a bleeding
problem or been told you have a bleeding disorder or problem:
During/after surgery
With dental procedures, extractions?
With trauma?
During childbirth or for heavy menses?
Ever had bruises with lumps?
2. Do you have or have you ever had:
Liver or kidney disease, a blood or bone marrow
disorder; a high or low platelet count?
3. Do you take aspirin, NSAIDs (provide common names), clopidogrel
(Plavix TM), warfarin, heparin?
No evaluation; usual care
No further evaluation;
usual care
Evaluate further: initial
laboratory tests andpossible referral (figure 4,
p 25)
Ask questions in Box 1 (p 21) and
the 3 questions above (if not alreadyasked), AND obtain history of
treatment (e.g., blood transfusion)
Examine for signs of bleeding or
underlying disease
Personal history of VWD
Abnormal laboratory test
Positive family history of a bleeding
disorder or bleeding
Patient is concerned about
bleeding; patient who has
unexplained anemia or historyof previous DDAVP use
Negative Positive
No Yes
Initial evaluation strategy to determine which patients would most benefit from further diagnostic evaluation for von Willebrand disease (VWD)
Left Upper Box: Individuals would be asked three questions about their personal or family bleeding history which, if any are positive, would
lead to a second set of questions selected for their sensitivity and specificity for VWD (Box1, p.21). Those patients answering positively to one
or more of the second set of questions would benefit from laboratory evaluation. Right Boxes: Patients presenting with specific information or
a concern about bleeding would be asked the Box 1 questions and the initial 3 questions if not already asked, and would also undergolaboratory evaluation.
Figure 3. In i t ia l Evaluat ion For VWD or Other Bleeding Disorders
7/31/2019 Von willbread.pdf
31/126
21Diagnosis and Evaluation
1. Do you have a blood relative who has a bleedingdisorder, such as von Willebrand disease orhemophilia?
2. Have you ever had prolonged bleeding from trivialwounds, lasting more than 15 minutes orrecurring spontaneously during the 7 days afterthe wound?
3. Have you ever had heavy, prolonged, or recurrentbleeding after surgical procedures, such astonsillectomy?
4. Have you ever had bruising, with minimal or noapparent trauma, especially if you could feel alump under the bruise?
5. Have you ever had a spontaneous nosebleed thatrequired more than 10 minutes to stop or neededmedical attention?
6. Have you ever had heavy, prolonged, or recurrentbleeding after dental extractions that requiredmedical attention?
7. Have you ever had blood in your stool, unex-plained by a specific anatomic lesion (such as anulcer in the stomach, or a polyp in the colon), thatrequired medical attention?
8. Have you ever had anemia requiring treatment orreceived blood transfusion?
9. For women, have you ever had heavy menses,characterized by the presence of clots greater thanan inch in diameter and/or changing a pad ortampon more than hourly, or resulting in anemiaor low iron level?
Symptoms
Epistaxis
Menorrhagia*
Bleeding afterdental extraction
Ecchymoses
Bleeding fromminor cuts orabrasions
Gingival bleeding
Postoperativebleeding
Hemarthrosis
Gastrointestinalbleeding
All typesVWD
(n = 264;137n = 1,885141)
%
Type 1 VWD(n = 42;142n = 671136)
%
Type 2 VWD(n = 497136)
%
Type 3 VWD(n = 66;136n = 38585)
%
Table 7. Common Bleeding Symptoms of Heal thy Individuals and Pat ients Who Have VWD
* Calculated for females above 13 to 15 years of age. 341 individuals were sent a questionnaire, but the precise number of patients responding was not provided. Study included women only. Study included males only.N.R., Not reported.
38.162.5
4760
28.651.5
49.250.4
36
26.134.8
19.528
6.38.3
14
5361
32
1731
50
36
2931
2047
23
5
63
32
39
N.R.
40
35
23
4
8
6677
5669
5370
N.R.
50
56
41
3745
20
Sources: Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, Turecek PL, Lillicrap D, Rand ML. von Willebrand diseasein a pediatric-based populationcomparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost2000 Sep;(3):401409; Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identifywomen with von Willebrand disease. J Am Med Womens Assoc2002;57(4):217218; and Laffan M, Brown SA, Collins PW, Cumming AM,Hill FG, Keeling D, Peake IR, Pasi KJ. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre DoctorsOrganization. Haemophilia 2004 May;10(3):199217.
4.622.7
2368.4
4.841.9
11.850
0.233.3
7.447.1
1.428.2
014.9
0.627.7
Normals(n = 500;137n= 341;138n = 88;139n= 60140)
%
Box 1 . Suggested Quest ions for Screening Persons for a Bleeding Disorder
7/31/2019 Von willbread.pdf
32/126
22 von Willebrand Disease
specificity of menorrhagia as a predictor of VWDcan be estimated as 520 percent. Three findings thatpredict abnormal menstrual blood loss of >80 mLinclude:
Clots greater than approximately 1 inch in diameter
Low serum ferritin Changing a pad or tampon more than hourly153
Identification of people who may require furtherevaluation for inherited bleeding disorders. Sinceother bleeding symptoms besides menorrhagia arereported frequently by persons who have apparentlynormal hemostasis, it is important to use questionsthat can best identify persons who have a truebleeding disorder. Sramek and colleagues138 useda written questionnaire with patients who had aproven bleeding disorder. When the responses werecompared to those of a group of healthy volunteers,
the most informative questions were related to:(1) prolonged bleeding after surgery, including afterdental extractions, and (2) identification of familymembers who have an established bleeding disorder(Table 8, columns 25). A history of muscle or jointbleeding may also be helpful when associated withthe above symptoms.
General questions that relate to isolated bleedingsymptomssuch as frequent gingival bleeding,profuse menstrual blood loss, bleeding after delivery,and epistaxis in the absence of other bleeding
symptomswere not informative.138 The study alsofound that an elaborate interview after referral toa hematologist was not particularly helpful whenattempting to distinguish persons who have atrue bleeding disorder from persons who have asuspected bleeding disorder, implying that theselection of those with bleeding disorders hadalready been made by the referring physician.138
Drews et al.139 attempted to develop a questionnaire-based screening tool to identify women who mightbenefit from a diagnostic workup for VWD. Theyconducted a telephone survey of 102 women whohad a diagnosis of type 1 VWD and were treated ata hemophilia treatment center compared with 88friends who were controls. With the exception ofpostpartum transfusions, all study variables werereported more frequently by women who had VWDthan by their friends (Table 8, columns 6 and 7).In addition, positive responses to multiple questionswere more likely to be obtained from patients who
have an inherited bleeding disorder.139 An importantlimitation of this study is that these women weremore symptomatic than most women diagnosedas having type 1 VWD, indicating a more severephenotype of the disease; this fact might decrease thesensitivity of the questions in the setting of persons who
have milder type 1 VWD and fewer symptoms.
More recently, Rodeghiero and colleagues155
compared responses to a standardized questionnaireobtained from 42 obligatory carriers of VWD (fromwell-characterized families) to responses from 215controls. The questionnaire covered 10 commonbleeding symptoms (including all symptoms in Table7, and postpartum hemorrhage), with assigned scoresfor each ranging from 0 (no symptoms) to 3 (severesymptoms, usually including hospitalization and/ortransfusion support). With this instrument, the
researchers found that having a cumulative totalbleeding score of 3 in men, or 5 in women, was veryspecific (98.6 percent) but not as sensitive (69.1percent) for type 1 VWD. Limitations of this studyinclude that it was retrospective and that the personadministering the questionnaire was aware of therespondents diagnosis. This questionnaire isavailable online.155
A similar retrospective casecontrol study154 used astandardized questionnaire like that of Rodegherio etal.155 to assess bleeding symptoms of 144 index caseswho had type 1 VWD, compared to 273 affectedrelatives, 295 unaffected relatives, and 195 healthycontrols. The interviewers were not blinded tosubjects status. At least one bleeding symptomwas reported by approximately 98 percent of indexcases, 89 percent of affected relatives, 32 percentof unaffected relatives, and 12 percent of healthycontrols. The major symptoms of affected persons(excluding index cases) included bleeding after toothextraction, nosebleeds, menorrhagia, bleeding intothe skin, postoperative bleeding, and bleeding fromminor wounds. Using a bleeding score calculatedfrom the data for comparison, the severity of bleedingdiminished with increasing plasma VWF, not only forsubjects who had low VWF levels but throughoutthe normal range as well. Although the meanbleeding score was significantly different betweenseveral groups, the distribution was sufficiently broadthat the bleeding score could not predict the affectedor unaffected status of individuals.
7/31/2019 Von willbread.pdf
33/126
23Diagnosis and Evaluation
SymptomOdds ratio
Family members have
an established bleedingdisorder
Profuse bleeding from
small wounds
Profuse bleeding at site
of tonsillectomy/
adenoidectomy
Easy bruising
Profuse bleeding after
surgery
Muscle bleeding (ever)
Frequent nosebleeds
Profuse bleeding at site
of dental extraction
Blood in stool (ever)
Family members with
bleeding symptoms
Joint bleeding (ever)
Menorrhagia
Hemorrhage at time
of delivery
Frequent gingival
bleeding
Hematuria (ever)
Table 8. Prevalences of Character ist i cs in Pat ients Who Have Diagnosed Bleeding Disorders Versus
Heal thy Controls
Sources: Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern
Med1995 Jul;155(13):14091415; Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identify women with von
Willebrand disease. J Am Med Womens Assoc2002;57(4):217218; and Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB,
Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease:results from a multicenter European study (MCMDM-1 VWD). J Thrombos Haemostas 2006;4:766773.
* Univariate and multivariate analyses from reference comparing 222 patients who had a known bleeding disorder (43 percent mild VWD)
to 341 healthy volunteers 138.
Compiled from responses to a questionnaire sent to 102 women, who had type 1 VWD, in a hemophilia treatment center.139
Compiled from interviews comparing affected vs. unaffected family members of patients who have type 1 VWD. The index cases (patients who
have VWD) were not included in the analysis (Tosetto et al. 2006, and personal communication from Dr. Francesco Rodeghiero on behalf ofcoauthors).154
CI, confidence interval
95% CI
97.5
67.2
27.7
12.7
23.0
13.3
3.5
39.4
2.8
28.6
8.6
5.4
5.3
2.8
3.2
50.5
30.0
11.5
9.9
5.8
4.8
3.8
3.2
2.8
2.5
2.5
2.5
2.1
0.7
0.5
9.8
52.9
9.8
61.8
54.9
13.7
20.6
50.0
76.5
12.5
202.9
8.1
111.1
1.2
111.9
3.0
32.3
1.3
26.4
0.7
31.4
0.9
15.7
0.9
11.3
0.7
11.7
0.7
9.4
0.6
10.2
0.6
9.9
0.3
13.5
0.3
2.0
0.12.3
38.3
248
28.4
159
8.0
96.1
8.0
20.2
10.6
50.1
6.4
27.7
2.0
6.2
20.6
75.5
1.7
4.6
15.0
54.6
4.8
15.2
3.0
9.8
2.3
12.0
1.9
4.2
1.85.6
4.8
17.3
42.8
62.9
4.8-
17.3
51.6
71.2
44.7
64.8
7.7
22.0
13.2
29.7
39.9
60.1
67.0
84.3
16.7
8.1
8.9
4.9
4.6
1.6
5.1
0.9
1.3
2.0
137.7
2.1
30.5
3.6
21.8
2.4
10.0
2.5
8.4
0.6
4.3
2.6
10.1
0.3
3.2
0.3
6.7
Univariate analysis*
Odds ratio 95% CI
Multivariate analysis*
Sensitivity 95% CI
Women who have VWD
Odds ratio 95% CI
Type 1 VWD families
7/31/2019 Von willbread.pdf
34/126
In a related study, bleeding symptoms were assessedwith the same questionnaire in 70 persons who wereobligatory carriers of type 3 VWD, 42 persons whowere obligate carriers of type 1 VWD (meaningaffected family members of index cases who hadtype 1 VWD), and 215 persons who were healthy
controls.156 Carriers of type 3 VWD were comparedwith carriers of type 1 VWD to address the questionof whether the distinct types of VWF mutationsassociated with these conditions predisposed to thesame or different severity of bleeding. Approximately40 percent of carriers of type 3 VWD, 82 percent ofcarriers of type 1 VWD, and 23 percent of healthycontrols had at least one bleeding symptom. Themajor bleeding symptoms in carriers of type 3 VWDwere bleeding into skin and postsurgical bleeding.The results suggest that carriers of type 3 VWD aresomewhat distinct, as they have bleeding symptoms
more frequently than healthy controls but lessfrequently than persons who have or are carriers oftype 1 VWD. Usually, carriers of type 1 VWD havelower VWF levels than carriers of type 3 VWD.
Family history. Although a family history that ispositive for an established bleeding disorder is usefulin identifying persons who are likely to have VWD,such a history is frequently not present. This is mostcommonly the case for persons who have milderforms of VWD and whose family members may haveminimal, if any, symptoms. As shown in Table 8, the
presence of a documented bleeding disorder in afamily member is extremely helpful in deciding whichpersons to evaluate further, whereas a family historyof bleeding symptoms is less helpful.
Box 1 (page 21) summarizes suggested questionsthat can be used to identify persons who should beconsidered for further evaluation for VWD withlaboratory studies.
Physical examination. The physical examinationshould be directed to confirm evidence for a bleedingdisorder, including size, location, and distribution of
ecchymoses (e.g., truncal), hematomas, petechiae, andother evidence of recent bleeding. The examinationshould also focus on findings that may suggest othercauses of increased bleeding, such as evidence of liverdisease (e.g., jaundice), splenomegaly, arthropathy,joint and skin laxity (e.g., Ehlers-Danlos Syndrome),telangiectasia (e.g., hereditary hemorraghictelangiectasia), signs of anemia, or anatomic lesionson gynecologic examination.
Acquired von Willebrand Syndrome (AVWS). Personswho have AVWS present with bleeding symptomssimilar to those described, except that the pastpersonal and family history are negative for bleedingsymptoms. AVWS may occur spontaneously or inassociation with other diseases, such as monoclonal
gammopathies, other plasma cell dyscrasias,lymphoproliferative diseases, myeloproliferativedisorders (e.g., essential thrombocythemia),autoimmune disorders, valvular and congenital heartdisease, certain tumors, and hypothyroidism.117,157
The evaluation should be tailored to findingconditions associated with AVWS.
Laboratory Diagnosis and Monitoring
An algorithm for using clinical laboratory studies
to make the diagnosis of VWD is summarized inFigure 4.
Ideally, a simple, single laboratory test could screenfor the presence of VWD. Such a screening testwould need to be sensitive to the presence of mosttypes of VWD and would have a low false-positiverate. Unfortunately, no such test is available. In thepast, the activated partial thromboplastin time (PTT)and bleeding time (BT) were recommended asdiagnostic tests. These tests were probably satisfactoryfor detecting severe type 3 VWD, but as variant VWDand milder forms of VWD were characterized, itbecame apparent that many of the persons who havethese conditions had normal PTT and normal BTresults.
An initial hemostasis laboratory evaluation (see Box2) usually includes a platelet count and completeblood count (CBC), PTT, prothrombin time (PT),and optionally either a fibrinogen level or a thrombintime (TT). This testing neither rules in nor rulesout VWD, but it can suggest whether coagulationfactor deficiency or thrombocytopenia might be thepotential cause of clinical bleeding. If the mucocuta-
neous bleeding history is strong, consider performing
24 von Willebrand Disease
CBC and platelet count
PTT PT Fibrinogen or TT (optional)
Box 2. Initial Laboratory Evaluation of Hemostasis
7/31/2019 Von willbread.pdf
35/126
25Diagnosis and Evaluation
Initial evaluation
(history and physical examination)
(See Figure 3)
Positive Negative
Possible referral for other appropriate
evaluation
1 or more tests
abnormalNo test
abnormal
Referral for other
appropriate evaluationOther cause identified, e.g.,
platelets*, isolated abnormal PT,
low fibrinogen, abnormal TT
No further evaluationLaboratory evaluation
Initial hemostasis tests
CBC and platelet count
PTT
PT
Fibrinogen or TT (optional)
If bleeding history is strong,
consider performing initial
VWD assays
Isolated prolonged PTT that
corrects on 1:1 mixing study,
or no abnormalities
Initial VWD assays
VWF:Ag
VWF:RCo
FVIII
Referral for selected specialized VWD
studies
Repeat initial VWD assays if necessary
Ratio of VWF:RCo to VWF:Ag
Multimer distribution
Collagen binding
RIPA or platelet binding
FVIII binding
Platelet VWF studies
DNA sequencing of VWF gene
Figure 4. Laboratory Assessment For VWD or Other Bleeding Disorders
* Isolated decreased platelets may occur in VWD type 2B.
Correction in the PTT mixing study immediately and after 2-hour incubation removes a factor VIII (FVIII) inhibitor from consideration.
Investigation of other intrinsic factors and lupus anticoagulant also may be indicated.
CBC, complete blood count; PT prothrombin time; PTT partial thromboplastin time; RIPA, ristocetin-induced platelet aggregation; TT, thrombintime; VWF:Ag, VWF antigen; VWF:RCo, VWF ristocetin cofactor activity.
If the initial clinical evaluation suggests a bleeding disorder, the initial hemostasis tests should be ordered, followed by or along with the next
tests (initial VWD assays) indicated in the algorithm. Referral to a hemostasis specialist is appropriate for help in interpretation, repeat test-ing, and specialized tests.
7/31/2019 Von willbread.pdf
36/126
initial VWD assays (VWF:Ag, VWF:RCo, and FVIII)at the first visit.
Some centers add a BT or a platelet function analyzer(PFA-100) assay to their initial laboratory tests.The BT test is a nonspecific test and is fraught with
operational variation. It has been argued that it wasa population-based test that was never developed totest individuals.158 Variables that may affect resultsinclude a crying or wiggling child, differences in theapplication of the blood pressure cuff, and thelocation, direction, and depth of the cut made bythe device.
This test also has a potential for causing keloidformation and scarring, particularly in non-Caucasianindividuals. The PFA-100 result has beendemonstrated to be abnormal in the majority ofpersons who have VWD, other than those who have
type 2N, but its use for population screening forVWD has not been established.159162 Persons whohave severe type 1 VWD or who have type 3 VWDusually have abnormal PFA-100 values, whereaspersons who have mild or moderate type 1 VWD andsome who have type 2 VWD may not have abnormalresults.163165 When persons are studied by usingboth the BT and PFA-100, the results are not alwaysconcordant.162,164,166
When using the PTT in the diagnosis of VWD,results of this test are abnormal only if the FVIII is
sufficiently reduced. Because the FVIII gene isnormal in VWD, the FVIII deficiency is secondary tothe deficiency of VWF, its carrier protein. In normalindividuals, the levels of FVIII and VWF:RCo areapproximately equal, with both averaging 100 IU/dL.In type 3 VWD, the plasma FVIII level is usually lessthan 10 IU/dL and represents the steady state of FVIIIin the absence of its carrier protein. In persons whohave type 1 VWD, the FVIII level is often slightlyhigher than the VWF level and may fall within thenormal range. In persons who have type 2 VWD(except for type 2N VWD in which it is decreased),
the FVIII is often 23 times higher than the VWFactivity (VWF:RCo).167,168 Therefore, the PTT isoften within the normal range. If VWF clearance isthe cause of low VWF, the FVIII reduction parallelsthat of VWF, probably because both proteins arecleared together as a complex.
Initial Tests for VWD
Box 3 lists the initial tests commonly used to detectVWD or low VWF. These three tests, readily availablein most larger hospitals, measure the amount of VWFprotein present in plasma (VWF:Ag), the function of
the VWF protein that is present as ristocetin cofactoractivity (VWF:RCo), and the ability of the VWF toserve as the carrier protein to maintain normal FVIIIsurvival, respectively. If any of the above tests isabnormally low, the next steps should be discussedwith a coagulation specialist, who may recommendreferral to a specialized center, and/or repeating thelaboratory tests plus performing additional tests.
VWF:Agis an immunoassay that measures theconcentration of VWF protein in plasma. Commonlyused methods are based on enzyme-linkedimmunosorbent assay (ELISA) or automated latex
immunoassay (LIA). As discussed below, thestandard reference plasma is critical and should bereferenced to the World Health Organization (WHO)standard. The persons test results should be reportedin international units (IU), either as internationalunits per deciliter (IU/dL) or as international unitsper milliliter (IU/mL). Most laboratories chooseIU/dL, because it is similar to the conventionalmanner of reporting clotting factor assays as apercentage of normal.
VWF:RCois a functional assay of VWF that measures
its ability to interact with normal platelets. Theantibiotic, ristocetin, causes VWF to bind to platelets,resulting in platelet clumps and their removal fromthe circulation. Ristocetin was removed from clinicaltrials because it caused thrombocytopenia. Thisinteraction was developed into a laboratory test thatis still the most widely accepted functional test forVWF. (In vivo, however, it is the high shear in themicrocirculation, and not a ristocetin-like molecule,that causes the structural changes in VWF that lead toVWF binding to platelets.)
26 von Willebrand Disease
VWF:Ag
VWF:RCo
FVIII
Box 3. Initial Tests for VWD
7/31/2019 Von willbread.pdf
37/126
27
Several methods are used to assess the plateletagglutination and aggregation that result fromthe binding of VWF to platelet GPIb induced byristocetin (ristocetin cofactor activity, or VWF:RCo).The methods include: (1) time to visible plateletclumping using ristocetin, washed normal platelets
(fresh or formalinized), and dilutions of patientplasma; (2) slope of aggregation during plateletaggregometry using ristocetin, washed normalplatelets, and dilutions of the persons plasma; (3)automated turbidometric tests that detect plateletclumping, using the same reagents noted above; (4)ELISA assays that assess direct binding of the personsplasma VWF to platelet GPIb (the GPIb may bederived from plasma glycocalicin) in the presenceof ristocetin;169171 and (5) the binding of amonoclonal antibody to a conformation epitope ofthe VWF A1 loop.172 Method 5 can be performed
in an ELISA format or in an automated lateximmunoassay. It is not based on ristocetin binding.The first three assays (above) may use platelet mem-brane fragments containing GPIb rather than wholeplatelets. The sensitivity varies for each laboratoryand each assay; in general, however, Methods 1 and 2,which measure platelet